IL288838B1 - Process for preparing oligonucleotides using a modified oxidation protocol - Google Patents

Process for preparing oligonucleotides using a modified oxidation protocol

Info

Publication number
IL288838B1
IL288838B1 IL288838A IL28883821A IL288838B1 IL 288838 B1 IL288838 B1 IL 288838B1 IL 288838 A IL288838 A IL 288838A IL 28883821 A IL28883821 A IL 28883821A IL 288838 B1 IL288838 B1 IL 288838B1
Authority
IL
Israel
Prior art keywords
equivalents
oxidation
days
formula
nucleoside
Prior art date
Application number
IL288838A
Other languages
Hebrew (he)
Other versions
IL288838A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL288838A publication Critical patent/IL288838A/en
Publication of IL288838B1 publication Critical patent/IL288838B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)

Description

WO 2020/249571 PCT/EP2020/065992 Process for the preparation of oligonucleotides using modified oxidation protocol.
The invention relates to a novel process for the production of a mixed P=O/P=S backbone oligonucleotide comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme ' nucleoside residue 5' nucleoside residue 3' nucleoside residue 3' nucleoside residue I 11 wherein the oxidation follows a particular oxidation protocol.
The oligonucleotide synthesis in principle is a stepwise addition of nucleotide residues to the 5'-terminus of the growing chain until the desired sequence is assembled.
As a rule, each addition is referred to as a synthetic cycle and in principle consists ofthe chemical reactions a!) de-blocking the protected hydroxyl group on the solid support, a2) coupling the first nucleoside as activated phosphoramidite with the free hydroxyl group on the solid support, a3) oxidizing or sulfurizing the respective P-linked nucleoside (phosphite triester) to form the respective phosphodiester (P=O) or the respective phosphorothioate (P=S); WO 2020/249571 PCT/EP2020/065992 -2- a4) optionally, capping any unreacted hydroxyl groups on the solid support; as) de-blocking the 5’ hydroxyl group of the first nucleoside attached to the solid support; a6) coupling the second nucleoside as activated phosphoramidite to form the respective P-linked dimer; a?) oxidizing or sulfurizing the respective P-linked dinucleotide (phosphite triester) to form the respective phosphodiester (P=O) or the respective phosphorothioate (P=S); as) optionally, capping any unreacted 5’ hydroxyl groups; a9) repeating the previous steps as to as until the desired sequence is assembled.
The principles of the oligonucleotide synthesis are well known in the art (see e.g. Oligonucleotide synthesis; Wikipedia, the free encyclopedia; https://en.wikipedia.org/wiki/Oligonucleotide synthesis, of March 15, 2016).
The oxidizing step is typically performed with an oxidation solution comprising iodine, an organic solvent, which as a rule is pyridine and water.
However, it was observed that when a freshly prepared oxidation solution has been applied, not only the desired oxidation of the intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II takes place, but also, as a side reaction, phosphorothioate internucleotide linkages present in the molecule may be affected by a P=S to P=O conversion at the internucleotide linkages which resulted in a higher than expected content of phosphodiester linkages within the compound of formula II.
Object of the invention therefore was to find an oxidation protocol which allows a selective oxidation of the phosphite triester compound of formula I into the phosphodiester compound of formula II without affecting the phosphorothioate internucleotide linkage.
It was found that the object of the invention could be reached with the process for the production of a mixed P=O/P=S backbone oligonucleotide which comprises the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme WO 2020/249571 PCT/EP2020/065992 ' nucleoside residue 5' nucleoside residue 3' nucleoside residue3' nucleoside residue III with an oxidation solution obtained by mixing iodine, an organic solvent, and water , and which is characterized in that the oxidation solution has been aged for a time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The term "Ci-6-alkyl" denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms, and in a more particular embodiment 1 to 4 carbon atoms. Typical examples include methyl, ethyl, propyl, isopropyl, n-butyl, z-butyl, sec-butyl, or t- butyl, preferably methyl or ethyl.
The term oligonucleotide as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleotides. For use as a therapeutically valuable oligonucleotide, oligonucleotides are typically synthesized as to 40 nucleotides, preferably 10 to 25 nucleotides in length.
The oligonucleotides may consist of optionally modified DNA or RNA nucleoside monomers or combinations thereof.
Optionally modified as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the nucleobase moiety.
Typical modifications can be the 2،-O-(2-Methoxyethyl)-substitution (2’-M0E) substitution in the sugar moiety or the locked nucleic acid (LNA), which is a modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and the 4' carbon.
WO 2020/249571 PCT/EP2020/065992 -4- The term modified nucleoside may also be used herein interchangeably with the term "nucleoside analogue" or modified "units" or modified "monomers".
The DNA or RNA nucleotides are as a rule linked by a phosphodiester (P=O) or a phosphorothioate (P=S) internucleotide linkage which covalently couples two nucleotides together.
In accordance with the invention at least one internucleotide linkage has to consist of a phosphorothioate (P=S). Accordingly, in some oligonucleotides all other internucleotide linkages may consist of a phosphodiester (P=O) or in other oligonucleotides the sequence of internucleotide linkages vary and comprise both phosphodiester (P=O) and phosphorothioate (P=S) intemucleotide linkages.
Accordingly the term mixed P=O/P=S backbone oligonucleotide refers to oligonucleotides wherein at least one intemucleotide linkage has to consist of a phosphorothioate (P=S).
The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are described with capital letters A, T, G and MeC (5-methyl cytosine) for LNA nucleoside and with small letters a, t, g, c and MeC for DNA nucleosides. Modified nucleobases include but are not limited to nucleobases carrying protecting groups such as tert-butylphenoxyacetyl, phenoxyacetyl, benzoyl, acetyl, isobutyryl or dimethylformamidino (see Wikipedia, Phosphoramidit-Synthese, https://de.wikipedia.org/wiki/Phosphoramidit- Synthese of March 24, 2016).
Preferably the oligonucleotide consists of optionally modified DNA or RNA nucleoside monomers or combinations thereof and is 10 to 40, preferably 10 to nucleotides in length.
The principles of the oligonucleotide synthesis are well known in the art (see e.g. Oligonucleotide synthesis; Wikipedia, the free encyclopedia; https://en.wikipedia.org/wiki/Oligonucleotide synthesis, of March 15, 2016).
Larger scale oligonucleotide synthesis nowadays is carried out in an automated manner using computer-controlled synthesizers.
WO 2020/249571 PCT/EP2020/065992 -5- As a rule, oligonucleotide synthesis is a solid-phase synthesis, wherein the oligonucleotide being assembled is covalently bound, via its 3'-terminal hydroxy group, to a solid support material and remains attached to it over the entire course of the chain assembly. Suitable supports are the commercial available macroporous polystyrene supports like the Primer support 5G from GE Healthcare or the NittoPhase®HL support from Kinovate.
The subsequent cleavage from the resin can be performed with concentrated aqueous ammonia. The protecting groups on the phosphate and the nucleotide base are also removed within this cleavage procedure.
As outlined above the process for the production of a mixed P=O/P=S backbone oligonucleotide is comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme ' nucleoside residue 5' nucleoside residue 3' nucleoside residue3' nucleoside residue I H with an oxidation solution obtained by mixing iodine, an organic solvent, and water and is characterized in that the oxidation solution has been aged for a time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
The mixed P=O/P=S backbone oligonucleotide comprises at least one phosphorothioate intemucleotide linkage.
The oxidation solution is typically a solution which can be obtained by mixing iodine, an organic solvent, and water.
The organic solvent can be selected from pyridine or from a C1-6 alkyl-substituted pyridine e.g. lutidine, but preferably from pyridine. A further organic solvent such as tetrahydrofuran may be present.
WO 2020/249571 PCT/EP2020/065992 -6- The oxidation solutions are commercially available, e.g. as oxidizer solutions from Sigma Aldrich (Merck). Alternatively, fresh solutions can be prepared using commercially available iodine and pyridine.
The volume ratio of pyridine or C1-6 alkyl-substituted pyridine to water can vary in a range from 1:1 to 20:1, preferably from to 5:1 to 15:, but more preferably is 9:1 .
The iodine concentration in the oxidation solution can be in the range of 10 mM to 100 mM, more preferably in the range between 20 mM to 50 mM.
The optimal period for the aging is largely determined by the temperature at which the oxidation solution is aged. While a low aging temperature results in longer aging period, a higher aging temperature significantly reduces the aging time.
It was found that the aging of the oxidation solution can take place at a temperature of °C to 100 °C, but preferably at a temperature of 30 °C to 60 °C.
The time period required for the aging of the oxidation solution has to be sufficient to effect selective oxidation of the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
As a rule the oxidation solution can be aged for a time period of at least 1 day, 3 days, days, 10 days, 15 days or at least 20 days.
The time period may, as mentioned, largely varies dependent on the aging temperature and can for an aging temperature of 30 °C to 35 °C vary between 10 days and 150 days, more typically between 20 days and 60 days, while for an aging temperature of °C to 65 °C can vary between 1 day and 30 days, more typically between 2 and 15 days.
The aging as a rule goes along with an increase of the conductivity (uS/cm) and a decrease of the pH. In a further embodiment of the invention the process of the present invention comprises the monitoring of the parameters pH and conductivity to determine the time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate intemucleotide linkages.
WO 2020/249571 PCT/EP2020/065992 -7- The amount of oxidant used in the oxidation reaction can be selected between 1.equivalents and 15 equivalents , more preferably between 1.5 equivalents and 4.5 equivalents, most preferably between 2 equivalents and 4 equivalents.
As a rule the oxidation reaction temperature is performed between 15 °C and 27 °C, more preferably between 18 °C and 24 °C.
By way of illustration the oligonucleotide can be selected from: ' - MeCs MeU0 MeC0A0GsTsAsAs MeCsAsTsTsGsAs MeCsA0 MeC0 MeC0As MeC- 3׳ The underlined residues are 2'-M0E nucleosides. The locations of phosphorothioate and phosphate diester linkages are designated by S and O, respectively. It should be noted that 2'- O-(2-methoxyethyl)-5-methyluridine (2'-M0E MeU) nucleosides are sometimes referred to as 2'-O-(2-methoxyethyl)ribothymidine (2'-M0E T).
The compounds disclosed herein have the following nucleobase sequences SEQ ID No. 1: cucagtaacattgacaccac WO 2020/249571 PCT/EP2020/065992 -8- Examples Example 1 Synthesis of 5' - MeCs MeU0 MeC0A0GsTsAsAs MeCs AsTsTsGsAs MeCsA0 MeC0 MeC0As MeC-3' The oligonucleotide was produced by standard phosphoramidite chemistry on solid phase at a scale of 2.20 mmol using an AKTA Oligopilot 100 and Primer Support Unylinker (NittoPhase LH Unylinker 330). In general 1.4 equiv of the DNA/2’-MOE-phosphoramidites were employed. Other reagents (dichloroacetic acid, 1-methylimidazole, 4,5- dicyanoimidazole, acetic anhydride, phenylacetyl disulfide, pyridine, triethylamine) were used as received from commercially available sources and reagent solutions at the appropriate concentration were prepared (see table 1 below) Cleavage and deprotection was achieved using ammonium hydroxide to give the crude oligonucleotide.
Table 1: Standard Reagent Solutions Deblock 10% dichloroacetic acid in toluene (v/v)Phosphoranudites 0.2 M in acetonitrileWil 1)( 1 aclnalor 1.0 M 4,5-dicyanoimidazole/ 0.1 M 1-methylimidazole in acetonitrileO1d1/er 0.05 M iodine in pyridine/water 9:1 (v/v); purchased from Sigma Aldrich or freshly prepared (see examples)Thiolalion 0.2 M phenylacetyl disulfide in 3-picoline/acetonitrile (1:1 v/v)( ap 1-Methylimidazole/pyridine/acetonitrile 2:3:5 (v/v/v)( ap B Acetic anhydride/acetonitrile 1:4 (v/v)1n1nc wash 50% triethylamine in acetonitrile (v/v)( leaxagcand Deprotection 28-32% aqueous ammonium hydroxide Example 2 Oxidizer aging experiments Example 2.1with purchased oxidizer solution WO 2020/249571 PCT/EP2020/065992 -9- Table 2: Oxidizer Batch 1 Oxidizer Batch 2Example Aging time at 30-35 JC (d)Total (P=O) ; content(%)Example Aging time at 30-35X (d)Total (P=O) ; content(%) 2.1 O1 7.8 3.1 O1 14.82.2 3 3.5 3.2 3 9.32.3 6 1.8 3.3 6 4.52.4 9 1.7 3.4 9 3.42.5 162 4.5 3.5 162 11.6 1 refers to the point in time when an aliquot from the commercial solution was taken for use-test and the thermal treatment of the remainder of the solution was started. This is not the same as the preparation time of the solution.the solution was not aged at 30-35 °C but stored at 1-15 °C starting at t = 0.refers to the percentage of molecules having a mass difference of 16 Da relative to the molecular mass of the desired compound determined in mass spectrometry, i.e. percentage of those molecule wherein 1 P=S linkage has been transformed into a P=O linkage.
Example 2.2with freshly prepared oxidizer solution: a) Preparation of iodine solution 1 .00 kg of water were added to 8.00 kg of pyridine at room temperature. 127 g of iodine were added. 0.827 kg of pyridine were added for rinsing and the mixture was stirred for 1 h under a positive pressure of dry nitrogen. b) Aging of iodine solution • Aging at 30-35 °C:800 mL aliquots were stored at 30-35 °C in amber glass bottles until use.• Aging at 60-65 °C:The material was kept in a jacketed glass reactor at 60-65 °C under a positive pressure of dry nitrogen until use.
WO 2020/249571 PCT/EP2020/065992 -10- Table 3: (aging at 30 °C-35 °C) Oxidizer Batch aged at 30 JC to 35 JCExample Aging time at 30-35 JC (d)Total (P=O).! content(%)PH Conductivity (uS/cm)2.6 O1 15.0 7.31 1862.7 9 8.2 6.38 11442.8 17 4.3 6.33 14402.9 29 2.0 6.21 15763.0 59 1.5 6.35 16543.1 122 1.2 6.18 1633 Table 4 (aging at 60 °C-65 °C) Oxidizer Batch aged at 60 "C to 65 JCExample Aging time at 60-65 °C (d)؛ ( Total (P=Ocontent(%)PH Conductivity (uS/cm)3.2 O1 15.0 7.31 1863.3 1 8.3 6.34 12153.4 3 1.5 6.21 17183.5 10 1.3 6.18 19703.6 30 1.2 6.09 2144 1 refers to the point in time when the solution was preparation of the solution was completed.refers to the percentage of molecules having a mass difference of 16 Da relative to the molecular mass of the desired compound determined in mass spectrometry, i.e. percentage of those molecule wherein 1 P=S linkage has been transformed into a P=O linkage.

Claims (9)

288838/ 02830250102- Claims:
1. Process for the production of a mixed P=O/P=S backbone oligonucleotide comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme 5' nucleoside residue 3' nucleoside residue 5' nucleoside residue 3' nucleoside residue III with an oxidation solution obtained by mixing iodine, an organic solvent and water, characterized in that the oxidation solution has been aged for a time period of at least 1 day, days, 5 days, 10 days, 15 days or at least 20 days at a temperature of 20 °C to 100 °C.
2. Process of claim 1, wherein the organic solvent is pyridine or a C1-6 alkyl-substituted pyridine.
3. Process of claim 2, wherein the volume ratio of pyridine or C1-6 alkyl-substituted pyridine to water is from 1:1 to 20:1, preferably from to 5:1 to 15:1, more preferably is 9:1.
4. Process of claims 2 or 3, wherein the iodine concentration in the oxidation solution is 10 mM to 100 mM, more preferably 20 mM to 50 mM.
5. Process of any one of claim 1 to 4, wherein the aging of the oxidation solution takes place at a temperature of 30 °C to 60 °C.
6. Process of any one of claims 1 to 5, wherein the process comprises the monitoring of the pH and the conductivity to determine the time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without converting the phosphorothioate internucleotide linkages.
7. Process of any one of claim 1 to 6, wherein the amount of oxidant used in the oxidation reaction is selected between 1.1 equivalents and 15 equivalents , more preferably 288838/ 02830250102- between 1.5 equivalents and 4.5 equivalents, most preferably between 2 equivalents and equivalents.
8. Process of any one of claim 1 to 7, wherein the reaction temperature for the oxidation reaction is selected between 15 °C and 27 °C, more preferably between 18 °C and °C.
9. Process of any one of claims 1 to 8, wherein the oligonucleotide consists of optionally modified DNA or RNA nucleoside monomers or combinations thereof and is 10 to 40, preferably 10 to 25 nucleotides in length. 10
IL288838A 2019-06-11 2020-06-09 Process for preparing oligonucleotides using a modified oxidation protocol IL288838B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19179310 2019-06-11
PCT/EP2020/065992 WO2020249571A1 (en) 2019-06-11 2020-06-09 Process for the preparation of oligonucleotides using modified oxidation protocol

Publications (2)

Publication Number Publication Date
IL288838A IL288838A (en) 2022-02-01
IL288838B1 true IL288838B1 (en) 2025-08-01

Family

ID=66821029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288838A IL288838B1 (en) 2019-06-11 2020-06-09 Process for preparing oligonucleotides using a modified oxidation protocol

Country Status (11)

Country Link
US (1) US12606584B2 (en)
EP (1) EP3983421A1 (en)
JP (2) JP2022536157A (en)
KR (1) KR102801138B1 (en)
CN (1) CN113993876B (en)
AU (1) AU2020292763B2 (en)
CA (1) CA3141195C (en)
IL (1) IL288838B1 (en)
MX (1) MX2021015197A (en)
TW (1) TWI848125B (en)
WO (1) WO2020249571A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220133878A (en) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 Method for preparing nucleic acid oligomers
CN115003680B (en) 2020-01-29 2025-01-28 住友化学株式会社 Method for preparing nucleic acid oligomers
CN114685572B (en) * 2022-06-02 2022-08-30 上海百力格生物技术有限公司 Oxidant composition for MGB nucleic acid probe synthesis and probe synthesis method
WO2026095005A1 (en) * 2024-10-31 2026-05-07 ペプチスター株式会社 Production of oligonucleic acid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239766A (en) 1990-09-14 1994-05-26 Hoechst Ag A process for the chemical synthesis of oligonucleotides
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5705621A (en) * 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
AR036122A1 (en) 2001-07-03 2004-08-11 Avecia Biotechnology Inc A COMPLEX OF SALT THAT INCLUDES AN N-ALQUILIMIDAZOL AND A 1,1-DIOXO-1,2-DIHIDRO-1L6-BENZO [D] -ISOTIAZOL-3-ONA AND A METHOD TO SYNTHEIZE OLIGONUCLEOTIDES USING PHOSPHORAMIDITE CHEMISTRY
US7205399B1 (en) * 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US6967247B2 (en) 2002-07-24 2005-11-22 Isis Pharmaceuticals, Inc. Deprotection of phosphorus in oligonucleotide synthesis
EP2017282A1 (en) 2006-02-27 2009-01-21 Nippon Shinyaku Co., Ltd. Method of capping oligonucleic acid
JP5320122B2 (en) * 2009-03-30 2013-10-23 株式会社小松製作所 Work vehicle and control method of work vehicle
CA2805546A1 (en) 2010-06-30 2012-01-05 Girindus America, Inc. A new method of using n-thio compounds for oligonucleotide synthesis
EP2823270B1 (en) 2012-03-09 2022-05-04 Promega Corporation pH SENSORS
WO2018019799A2 (en) 2016-07-27 2018-02-01 F. Hoffmann-La Roche Ag Oligonucleotide synthesis
CN110573626B (en) 2017-04-28 2024-05-03 豪夫迈·罗氏有限公司 Antibody selection methods
CN107474091B (en) 2017-07-21 2019-08-23 南开大学 The synthesis and application of 5- aldehyde radical cytidine phosphoramidite monomer of photosensitive protective group protection and preparation method thereof and oligonucleotide
US20220251128A1 (en) * 2019-05-17 2022-08-11 Ionis Pharmaceuticals, Inc. Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphodiester linkages

Also Published As

Publication number Publication date
JP2022536157A (en) 2022-08-12
AU2020292763B2 (en) 2022-12-08
TWI848125B (en) 2024-07-11
TW202112795A (en) 2021-04-01
MX2021015197A (en) 2022-01-18
JP7798962B2 (en) 2026-01-14
US20230295207A1 (en) 2023-09-21
BR112021025026A2 (en) 2022-01-25
CA3141195C (en) 2023-12-19
US12606584B2 (en) 2026-04-21
EP3983421A1 (en) 2022-04-20
IL288838A (en) 2022-02-01
WO2020249571A1 (en) 2020-12-17
CA3141195A1 (en) 2020-12-17
CN113993876B (en) 2024-06-14
JP2024112974A (en) 2024-08-21
KR102801138B1 (en) 2025-04-25
AU2020292763A1 (en) 2022-01-20
KR20220007665A (en) 2022-01-18
CN113993876A (en) 2022-01-28

Similar Documents

Publication Publication Date Title
JP7798962B2 (en) Method for preparing oligonucleotides using a modified oxidation protocol
US6114519A (en) Synthesis of sulfurized oligonucleotides
US20240092823A1 (en) Process for the de-tritylation of oligonucleotides
AU2022291626A1 (en) Improved process for preparing imetelstat
JP7777576B2 (en) Method for the preparation of oligonucleotides using a modified oxidation protocol
Perez-Rentero et al. Novel oligonucleotide analogues containing a morpholinoamidine unit
HK40085830A (en) Process for the preparation of oligonucleotides using modified oxidation protocol
HK40060364A (en) Process for the preparation of oligonucleotides using modified oxidation protocol
WO2026082783A1 (en) Synthesis of thiolated oligonucleotides without capping and without recirculation of the thiolating agent
HK40085830B (en) Process for the preparation of oligonucleotides using modified oxidation protocol
Sobczak et al. DNA oligonucleotides with stereodefined phenylphosphonate and phosphonothioate internucleotide bonds: synthesis and physico-chemical properties.
Wengel et al. Chemistry of Locked Nucleic Acids (LNA) Design, Synthesis and Bio-Physical Properties
JP2011517695A (en) Novel process for producing oligonucleotides containing 5'-phosphate monoester or 5'-thiophosphate monoester ends
JPH04330093A (en) Production of oligoribonucleotide
WO2002083702A1 (en) Process for selective n-acylation of purine nucleosides
HK40026576A (en) Improved process for preparing imetelstat
Porcher et al. Chemical Synthesis of DNA and RNA Containing Modified Nucleotides